Bio Medica Laboratories Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Bio Medica Laboratories Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
EBITDA for the quarter: ₹510 lakhs, up 25% year-on-year (YoY).
From Bio Medica Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 14 Nov 2026.
How did Bio Medica Laboratories' revenue grow in the September 2026 quarter?
See what Bio Medica Laboratories Ltd said on revenue & sales performance — free account, 30 seconds.
What happened to Bio Medica Laboratories' margins in Q2 FY27?
EBITDA for the quarter: ₹510 lakhs, up 25% year-on-year (YoY).
Locked: what Bio Medica Laboratories Ltd said on margins
Also locked on this page: revenue, capex, fundraising
Free account, 30 seconds. No card needed.
What capex is Bio Medica Laboratories planning?
See what Bio Medica Laboratories Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Bio Medica Laboratories raising money or cutting debt?
The Consolidated Cash Flow Statement for the year ended 30th September 2026 shows a significant increase…
Locked: what Bio Medica Laboratories Ltd said on fundraising
Also locked on this page: revenue, margins, capex
Free account, 30 seconds. No card needed.
How big is Bio Medica Laboratories' order book?
More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q2 FY27)
11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sotac Pharmaceuticals (Q2 FY27)
7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how
- Syncom Formulations (India) (Q2 FY27)
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F
- Innova Captab (Q2 FY27)
Revenue from Operations for Q2 FY27 was ₹496.3 crore, a 30.5% year-on-year (YoY) increase from ₹380.4 crore in Q2 FY26 (Page 11). Key investor presentation take
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Bio Medica Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Bio Medica Laboratories Ltd Q2 FY27 results?
EBITDA for the quarter: ₹510 lakhs, up 25% year-on-year (YoY).
What is Bio Medica Laboratories Ltd share price analysis?
Bio Medica Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 15.9 with a market cap of ₹189 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Bio Medica Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.